Safe and effective preventative Epstein-Barr Virus (EBV) vaccine
This invention provides a safe Epstein-Barr Virus vaccine, which does not introduce chromosomal instabilities associated with cancer development.
Experts estimate that an EBV vaccine could prevent 2% of all cancer cases worldwide.
Until now no method for producing a safe and efficient vaccine against EBV has been devel-oped.
This vaccine uses “virus-like particles” (VLP), devoid of detectable genetic material, to mimic an EBV infectious particle. While these particles prompt the body to mount an immune response they are themselves innoc-uous, thus making the vaccine much safer.
This vaccine lacks the ability of EBV particles to induce chromosome instability and chromo-somal associated with cancer development. In particular, EBV particles in this vaccine do not enter the cytosol and/or nucleus of cells, mak-ing it significantly safer than existing alterna-tives.
Prevention from EBV disease
Convincing in vitro and in vivo data are avail-able showing the absence of chromosomal instability after treatment with the new genera-tion VLP. Animal studies looking at safety and efficacy of the VLPs are currently being con-ducted.
Publikationen & Verweise
1. Shumilov A, et al. Epstein-Barr virus parti-cles induce centrosome amplification and chromosomal instability. Nat Commun. 2017 Feb 10;8:14257. doi: 10.1038/ncomms14257.
2. Patent WO2013098364 “Second genera-tion virus-like particles from Epstein-Barr Viruses for vaccination purposes”.
Weitere Information zum Herunterladen
- 73 Ki